Reactivity of direct assays for Low-Density Lipoprotein (LDL) cholesterol toward charge-modified LDL in hypercholesterolemia

Circulation Journal

Volumn 76, Issue 9, 2012, Pages 2241-2248

  Zhang, Bo ^a   Kawachi, Emi ^a   Matsunaga, Akira ^a   Imaizumi, Satoshi ^a   Noda, Keita ^a   Uehara, Yoshinari ^a   Miura, Shin Ichiro ^a   Yoshinaga, Kazuhiko ^a   Kuroki, Masahide ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Capillary isotachophoresis; Charge modified LDL subfraction; Electronegative LDL; Homogenous assay for LDL C; Hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; ROSUVASTATIN;

ARTICLE; ASSAY; CARDIOVASCULAR RISK; CHEMICAL PARAMETERS; CHOLESTEROL BLOOD LEVEL; DIRECT ASSAY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; ISOTACHOPHORESIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PROTEIN DETERMINATION; PROTEIN LOAD; PROTEIN SIZE; SOLUBILIZATION; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION;

APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CORONARY DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; ULTRACENTRIFUGATION;

EID: 84865525821     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0381     Document Type: Article

References (38)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-732.
3. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
4. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem 2010; 56: 977-986.
5. Yamashita S, Kawase R, Nakaoka H, Nakatani K, Inagaki M, Yuasa-Kawase M, et al. Differential reactivities of four homogeneous assays for LDL-cholesterol in serum to intermediate-density lipoproteins and small dense LDL: Comparisons with the Friedewald equation. Clin Chim Acta 2009; 410: 31-38.
6. Otokozawa S, Ai M, Asztalos BF, White CC, Demissie-Banjaw S, Cupples LA, et al. Direct assessment of plasma low density lipoprotein and high density lipoprotein cholesterol levels and coronary heart disease: Results from the Framingham Offspring Study. Atherosclerosis 2010; 213: 251-255.
7. Tanno K, Okamura T, Ohsawa M, Onoda T, Itai K, Sakata K, et al. Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population. Clin Chim Acta 2010; 411: 1774-1780.
8. Mora S, Rifai N, Buring JE, Ridker PM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem 2009; 55: 888-894.
9. Schaefer EJ, Otokozawa S, Ai M. Limitations of direct methods and the reference method for measuring HDL and LDL cholesterol. Clin Chem 2011; 57: 1081-1083; author reply 1083.
10. Rifai N, Warnick GR, Dominiczak MH. Handbook of lipoprotein testing. 2nd edition. Washington, DC: AACC Press, 2000.
11. Sanchez-Quesada JL, Benitez S, Ordonez-Llanos J. Electronegative low-density lipoprotein. Curr Opin Lipidol 2004; 15: 329-335.
12. Schmitz G, Mollers C, Richter V. Analytical capillary isotachophoresis of human serum lipoproteins. Electrophoresis 1997; 18: 1807-1813.
13. Bottcher A, Schlosser J, Kronenberg F, Dieplinger H, Knipping G, Lackner KJ, et al. Preparative free-solution isotachophoresis for separation of human plasma lipoproteins: Apolipoprotein and lipid composition of HDL subfractions. J Lipid Res 2000; 41: 905-915.
14. Temelkova-Kurktschiev T, Hanefeld M, Leonhardt W. Small dense low-density lipoprotein (LDL) in non-insulin-dependent diabetes mellitus (NIDDM): Impact of hypertriglyceridemia. Ann NY Acad Sci 1997; 827: 279-286.
15. Sanchez-Quesada JL, Camacho M, Anton R, Benitez S, Vila L, Ordonez-Llanos J. Electronegative LDL of FH subjects: Chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis 2003; 166: 261-270.
16. Mello AP, da Silva IT, Abdalla DS, Damasceno NR. Electronegative low-density lipoprotein: Origin and impact on health and disease. Atherosclerosis 2011; 215: 257-265.
17. Japanese Association of Medical Techonologists (JMAT). JMAT Clinical Laboratory Quality Control Survey Report. Tokyo, JMAT, 311, 2010.
18. Saku K, Zhang B, Noda K. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): The PATROL trial. Circ J 2011; 75: 1493-1505.
19. Zhang B, Bottcher A, Imaizumi S, Noda K, Schmitz G, Saku K. Relation between charge-based apolipoprotein B-containing lipoprotein subfractions and remnant-like particle cholesterol levels. Atherosclerosis 2007; 191: 153-161.
20. Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H, et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem 2007; 53: 2128-2135.
21. Zhang B, Matsunaga A, Rainwater DL, Miura S, Noda K, Nishikawa H, et al. Effects of rosuvastatin on electronegative LDL as characterized by capillary isotachophoresis: The ROSARY Study. J Lipid Res 2009; 50: 1832-1841.
22. Zhang B, Uehara Y, Hida S, Miura S, Rainwater DL, Segawa M, et al. Effects of reconstituted HDL on charge-based LDL subfractions as characterized by capillary isotachophoresis. J Lipid Res 2007; 48: 1175-1189.
23. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDLcholesterol: A critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002; 48: 236-254.
24. Zhang B, Kaneshi T, Ohta T, Saku K. Relation between insulin resistance and fast-migrating LDL subfraction as characterized by capillary isotachophoresis. J Lipid Res 2005; 46: 2265-2277.
25. Zhang B, Tomura H, Kuwabara A, Kimura T, Miura S, Noda K, et al. Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis 2005; 178: 199-205.
26. Zhang B, Miura S, Yanagi D, Noda K, Nishikawa H, Matsunaga A, et al. Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: The SPECIAL Study. Atherosclerosis 2008; 201: 353-359.
27. Zhang B, Maeda N, Okada K, Tatsukawa M, Sawayama Y, Matsunaga A, et al. Association between fast-migrating low-density lipoprotein subfraction as characterized by capillary isotachophoresis and intima-media thickness of carotid artery. Atherosclerosis 2006; 187: 205-212.
28. Zhang B, Matsunaga A, Saku K, Nakano S, Yamada T. Associations among plasma lipoprotein subfractions as characterized by analytical capillary isotachophoresis, apolipoprotein E phenotype, Alzheimer disease, and mild cognitive impairment. Arterioscler Thromb Vasc Biol 2004; 24: e144-e146.
29. SAS Institute Inc. SAS OnlineDoc 9.2. Cary, NC, USA: SAS Institute, 2009.
30. Nohara R, Daida H, Hata M, Kaku K, Kawamori R, Kishimoto J, et al. Effect of intensive lipid-lowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: Justification for Atherosclerosis Regression Treatment (JART) study. Circ J 2012; 76: 221-229.
31. Okada K, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, et al. Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: Subanalysis of the TWINS Study. Circ J 2012; 76: 1197-1202.
32. Soeda T, Uemura S, Okayama S, Kawakami R, Sugawara Y, Nakagawa H, et al. Intensive lipid-lowering therapy with rosuvastatin stabilizes lipid-rich coronary plaques: Evaluation using dual-source computed tomography. Circ J 2011; 75: 2621-2627.
33. Ikewaki K, Ayaori M. Strong statins as the major players for dyslipidemia in high-risk patients: Are they all the same or not? Circ J 2011; 75: 1326-1327.
34. Sakaue T, Hirano T, Yoshino G, Sakai K, Takeuchi H, Adachi M. Reactions of direct LDL-cholesterol assays with pure LDL fraction and IDL: Comparison of three homogeneous methods. Clin Chim Acta 2000; 295: 97-106.
35. Contois JH, Warnick GR, Sniderman AD. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J Clin Lipidol 2011; 5: 264-272.
36. Warnick GR. Lack of agreement of homogeneous assays with the reference method for LDL-cholesterol may not indicate unreliable prediction of risk for cardiovascular disease. Clin Chem 2002; 48: 1812-1814; author reply 1814-1815.
37. van Deventer HE, Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, et al. Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. Clin Chem 2011; 57: 490-501.
38. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, et al. Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55: 407-419.